ArticleJournal of materials science. Materials in medicine2025
LR-PRP-saturated bioactive bovine-derived decellularized pericardium accelerates osteogenesis in a rabbit bone defect model.
Article in Journal of materials science. Materials in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Combining decellularized biological scaffolds with PRP can prevent the rapid inactivation of growth factors and achieve their controlled and sustained release during tissue regeneration. Therefore, the purpose of this study was to evaluate the combined effect of decellularized bovine pericardium (dBP) and leukocyte-rich platelet-rich plasma (LR-PRP) on the bone repair in a rabbit femoral defect model. Bovine pericardium was decellularized using the Trypsin-Triton X-SDS protocol and histologically assessed. Unicortical bone defects were surgically created in the femur of rabbits (n = 6) and randomly assigned to three treatment allocations: (1) untreated control, (2) LR-PRP, and (3) LR-PRP + dBP-treated defects. Bone defect healing was evaluated using quantitative computed tomography (CT) and histopathological analyses. The dBP achieved 99.2% nucleus removal, retained about 34.3% of the sulfated glycosaminoglycan, and maintained a collagen content similar to the native pericardia. The CT voxel values of the defects treated with the LR-PRP + dBP increased by +33.2% and +56.2% at 2 and 4 weeks after surgery, respectively, compared to the control defects. As well, a significant rise in the CT values was observed in the LR-PRP + dBP treatment compared to the LR-PRP treatment alone at 2 weeks (p = 0.03) and 4 weeks (p = 0.02). Histopathologically, the LR-PRP + dBP treatment achieved higher bone repair scores with a significantly higher nascent bone area fraction (87.8%) compared to the LR-PRP (54%). These findings highlight the synergistic effect of dBP and LR-PRP, offering promising prospects in developing biocompatible scaffolds for enhancing bone repair.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.